Limited Reporting of Adverse Events Tied to Regenerative Treatments Leaves Consumers Vulnerable

The Food and Drug Administration (FDA) has taken a series of actions in recent years to crack down on businesses marketing high-risk, unapproved regenerative medicine interventions, including unproven stem cell treatments, but more needs to be done to ensure consumers are protected.

Read the full article here

Related Articles